Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses

European Journal of Pharmacology

Volumn 356, Issue 2-3, 1998, Pages 207-213

  Willoughby, Scott R ^a   Chirkov, Yuliy Y ^a   Kennedy, Jennifer A ^a   Murphy, Geraldine A ^a   Chirkova, Larissa P ^a   Horowitz, John D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Amiodarone; Carnitine palmitoyltransferase 1; Etomoxir; Perhexiline; Platelet aggregation; Trimetazidine

Indexed keywords

AMIODARONE; CARNITINE PALMITOYLTRANSFERASE; ETOMOXIR; GLYOXYLIC ACID DERIVATIVE; LONG CHAIN FATTY ACID; MALONYL COENZYME A; PERHEXILINE; TRIMETAZIDINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FATTY ACID METABOLISM; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADULT; AGED; AMIODARONE; BLOOD PLATELETS; CARDIOVASCULAR AGENTS; CARNITINE O-PALMITOYLTRANSFERASE; CASE-CONTROL STUDIES; ENZYME INHIBITORS; EPOXY COMPOUNDS; FATTY ACIDS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERHEXILINE; PLATELET AGGREGATION; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 0031757899     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00527-5     Document Type: Article

References (28)

1. Astarie-Dequeker, C., Joulin, Y., Devynck, M.A., 1994. Inhibitory effect of trimetazidine on thrombin-induced aggregation and calcium entry into human platelets. J. Cardiovasc. Pharmacol. 23, 401-407.
2. Belcher, P.R., Drake-Holland, A.J., Hynd, J.W., Noble, M.I.M, 1993. Effects of trimetazidine on in vivo coronary arterial platelet thrombosis. Cardiovasc. Drugs Ther. 7, 149-157.
3. Bielefeld, D.R., Vary, T.C., Neely, J.R., 1985. Inhibition of carnitine palmitoyl-CoA transferase activity and fatty acid oxidation by lactate and oxfenicine in cardiac muscle. J. Mol. Cell. Cardiol. 17, 619-625.
4. Chirkov, Y.Y., Naujalis, J.I., Sage, R.E., Horowitz, J.D., 1993. Antiplatelet effects of nitroglycerin in healthy subjects and in patients with stable angina pectoris. J. Cardiovasc. Pharmacol. 21, 384-389.
5. 1. J. Cardiovasc. Pharmacol. 25, 961-966.
6. Deschamps, D., DeBeco, V., Fisch, C., Fromenty, B., Guillouzo, A., Pessayre, D., 1994. Inhibition by perhexiline of oxidative phosphory-lation and the β-oxidation of fatty acids: possible role in pseudoalcholic liver lesions. Hepatology 19, 948-961.
7. Devynck, M.A., Le Quan Sang, K.H., Joulin, Y., Mazeaud, M., 1993. Acute membrane effects of trimetazidine in human platelets. Eur. J. Pharmacol. 245, 105-110.
8. Donabedian, R., Nemerson, Y., 1971. Fatty acid oxidation by human platelets and its stimulation by thrombin. Am. J. Physiol. 221, 1283-1286.
9. Fantini, E., Demaison, L., Sentex, F., Grynberg, A., Athias, P., 1994. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J. Mol. Cell. Cardiol. 26, 949-958.
10. Fromenty, B., Fisch, C., Berson, A., Letteron, P., Larrey, D., Pessayre, D., 1990. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the level of complex I and complex II. J. Pharmacol. Exp. Ther. 255, 1377-1384.
11. Higgins, A.J., Morville, M., Burges, R.A., Blackburn, K.J., 1981. Mechanism of action of oxfenicine on muscle metabolism. Biochem. Biophys. Res. Commun. 100, 291-296.
12. Higuchi, H., Hayashi, M., Sano, I. et al., 1981. Effects of trimetazidine granules (Vastarel F) in platelet adhesiveness and aggregation in patients with ischemic heart disease. J. Nissei. Hosp. 3, 89-95.
13. Iida, R., Takeyama, N., Iida, N., Tanaka, T., 1991. Characterization of overt carnitine palmitoyltransferase in rat platelets; involvement of insulin on its regulation. Mol. Cell. Biochem. 103, 23-30.
14. Iida, N., Iida, R., Takeyama, N., Tanaka, T., 1993. Increased platelet aggregation and fatty acid oxidation in diabetic rats. Biochem. Mol. Biol. Int. 30, 177-185.
15. Ishikura, H., Takeyama, N., Tanaka, T., 1992. Effects of 2-tetradecyl-glycidic acid on rat platelet metabolism and aggregation. Biochim. Biophys. Acta 1128, 193-198.
16. Jeffrey, F.M.H., Alvarez, L., Diczku, V., Sherry, D., Malloy, C.R., 1995. Direct evidence that perhexiline modifies myocardial substrate utilisation from fatty acid to glycolytic sources. J. Cardiovasc. Pharmacol. 25, 469-472.
17. Kennedy, J.A., Horowitz J.D., 1998. Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart. Cardiovasc. Drugs Ther.
18. Kennedy, J.A., Unger, S.A., Horowitz, J.D., 1996. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem. Pharmacol. 52, 273-280.
19. Kinlough-Rathbone, R.L., Packham, M., Mustard, F.J., 1983. Platelet aggregation. In: Harker, L.A., Zimmerman, T.A.(Eds.), Measurements of Platelet Function. Churchill Livingstone, Edinburgh, pp. 64-91.
20. Kiorpes, T.C., Hoerr, D., Ho, W., Weaner, L.E., Inman, M.G., Tutwiler, G.F., 1984. Identification of 2-tetradecylglycidyl coenzyme A as the active form of methyl 2-tetradecylglycidate (methyl palmoxirate) and its characterization as an irreversible, active site-directed inhibitor of carnitine palmitoyltransferase A in isolated rat liver mitochondria. J. Biol. Chem. 259, 9750-9755.
21. McGarry, J.D., Leatherman, G.F., Foster, D.W., 1978. Carnitine palmitoyltransferase: I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. J. Biol. Chem. 253, 4128-4136.
22. 2+-antagonistic vasodilators, diltiazem, nifedipine, perhexiline, and verapamil, on platelet aggregation in vitro. Arzneimittel-Forschung 31, 1131-1134.
23. Stephens, T.W., Higgins, A.J., Cook, G.A., Harris, R.A., 1985. Two mechanisms produce tissue-specific inhibition of fatty acid oxidation by oxfenicine. Biochem. J. 227, 651-660.
24. Stewart, S., Voss, D.W., Northey, D.L., Horowitz, J.D., 1996. Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy. Ther. Drug Monit. 18, 635-639.
25. Unger, S.A., Robinson, M.A., Horowitz, J.D., 1997. Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis. Aust. New Zealand J. Med. 27, 24-27.
26. Vaughan Williams, E.M, 1980. Anti-arrhythmic action and the puzzle of perhexiline. Academic Press, London.
27. Vollset, S.E., Farstad, M., 1979. A study of assay conditions for palmitoyl-CoA synthetase and carnitine palmitoyltransferase in homogenates of human blood platelets. Scand. J. Clin. Lab. Invest. 39, 15-21.
28. Willoughby, S.R., Chirkova, L.P., Horowitz, J.D., Chirkov, Y.Y., 1996. Multiple agonist induction of aggregation: an approach to examine anti-aggregatory effects in vitro. Platelets 7, 329-333.